Novo Nordisk Addresses Innovation in Diabetes Care in Second Issue of Industry Resource for Information on Diabetes and Chronic Disease
PRINCETON, N.J., July 12 /PRNewswire/ -- Novo Nordisk Inc., a global healthcare company and leader in diabetes care, today announced the second issue of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.
The second issue of the Novo Nordisk BlueSheet examines how insulin has evolved over the last 90 years, how it is developed today, the use of insulin devices in the U.S., and the outlook for next generation insulins. Each quarter, the Novo Nordisk BlueSheet will highlight key issues in diabetes prevention, detection, treatment and care, as well as related topics from the legislative process to public education.
To read the Novo Nordisk BlueSheet, go to: http://press.novonordisk-us.com/bluesheet.
"Innovation and scientific research and discovery are our most powerful tools in defeating diabetes with better methods of disease prevention, detection, treatment, and care," said Jerzy Gruhn, president of Novo Nordisk Inc. "At Novo Nordisk, we are committed to building an environment that supports the discovery of new products and solutions that can significantly impact the millions of people living with diabetes."
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.
SOURCE Novo Nordisk Inc.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.